'We Know We Will Emerge Stronger In The U.S.,' Says Ranbaxy CEO Atul Sobti: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Indian generic firm's new chief executive talks about adapting to majority ownership by Daiichi Sankyo and about being under the FDA magnifying glass.
You may also be interested in...
As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
MUMBAI - Less than one year after acquiring a 64 percent equity stake in India's Ranbaxy for $4.6 billion, Japanese drug maker Daiichi Sankyo has taken complete control of the company's management after reaching an "amicable" agreement on the exit of Malvinder Singh, the grandson of Ranbaxy's founder, and two other directors: Sunil Godhwani and Balinder Dhillon
Daiichi Sankyo announced May 12 its first annual loss for fiscal year 2008 since its 2005 merger with Sankyo Pharmaceutical. The third-largest Japanese drug maker announced a net loss of ¥335.8 billion, compared to ¥97.6 billion in net profit for FY2007. The huge loss is a direct result of ¥351.3 billion in write offs for Daiichi Sankyo's Indian subsidiary Ranbaxy Laboratories, which has been crippled by an export ban and investigation by U.S. FDA
MUMBAI - U.S. FDA conducted inspections of three manufacturing sites belonging to Indian drug maker Cipla and issued nine to 10 "Inspectional Observations" on various manufacturing issues. The manufacturing sites inspected by FDA are in Goa, Kurkumbh and Bangalore